

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/990,909	
			Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
			Art Unit	1645	
Sheet	1	of	7	Examiner Name	Albert Mark Navarro
				Attorney Docket Number	41012-705.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Claim Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5,439,935	08/08/1995	Rawlings et al.	
	2.	US 5,476,661	12/19/1995	Pillai et al.	
	3.	US 5,776,917	07/07/1998	Blank et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Claim Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
	4.	None.				

Continued on the next page with more references.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial of reference provided, whether or not checked off in accordance with MPEP 609. Enter line through citation if not in performance and not considered. Include only this form with each communication to applicant. *Applicant's unique status designations must be optional. *See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the documents, by the two-letter code (WIPO Standard ST.3). *The relevant patent documents, the indication of the year of the filing of the European patent, the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 182 and 37 CFR 1.14. This collection is determined to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form within suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FR202 OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (toll-free 866-9199) and select option 2.

Attorney Docket No. 41012-705.201

- 1 -

4399755_1.DOCX

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MN/

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/990,909	
			Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
			Art Unit	1645	
			Examiner Name	Albert Mark Navarro	
Sheet	2	of	7	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	5.	ANG, et al. Biological role and regulation of the universally conserved heat shock proteins. <i>J Biol Chem.</i> 1991 Dec 25;266(36):24233-6.		
	6.	ARRIBAS, et al. A comparative study of the chymotrypsin-like activity of the rat liver multicatalytic proteinase and the ClpP from <i>Escherichia coli</i> . <i>J Biol Chem.</i> 1993 Oct 5;268(28):21165-71.		
	7.	ARRIGO, et al. Expression of heat shock proteins during development in <i>Drosophila</i> . <i>Results Probl Cell Differ.</i> 1991;17:106-19.		
	8.	AUSTIC. Development and adaptation of protein digestion. <i>J Nutr.</i> 1985 May;115(5):686-97.		
	9.	AWAZUHARA, et al. Antigenicity of the proteins in soy lecithin and soy oil in soybean allergy. <i>Clin Exp Allergy.</i> 1998 Dec;28(12):1559-64.		
	10.	BEILMANN, et al. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. <i>Blood.</i> 1997 Dec 1;90(11):4450-8.		
	11.	BOROWITZ, et al. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. <i>J Pediatr.</i> 1995 Nov;127(5):681-4.		
	12.	BOYD, et al. Positively charged amino acid residues can act as topogenic determinants in membrane proteins. <i>Proc Natl Acad Sci U S A.</i> 1989 Dec;86(23):9446-50.		
	13.	BRUHAT, et al. Amino acid limitation induces expression of CHOP, a CCAAT/enhancer binding protein-related gene, at both transcriptional and post-transcriptional levels. <i>J Biol Chem.</i> 1997 Jul 11;272(28):17588-93.		
	14.	CARROCCIO, et al. Secondary impairment of pancreatic function as a cause of severe malabsorption in intestinal giardiasis: a case report. <i>Am J Trop Med Hyg.</i> 1997 Jun;56(6):599-602.		
	15.	CARROCCIO, et al. Secrelin-cerulein test and fecal chymotrypsin concentration in		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in accordance with MPEP 609. Draw line through citation if not in compliance and not considered. Include copy of this form with sent communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is requested by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 42, and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing, and submitting the completed application form to the ERO/PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1469, Alexandria, VA 22313-1469. DO NOT SEND FEE OR UNCOMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9196 (1-800-786-9196) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/990,909	
			Filing Date	November 16, 2001	
			First Named Inventor	Jean M. Fallon	
			Art Unit	1645	
			Examiner Name	Albert Mark Navarro	
Sheet	3	of	7	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		1 st
		children with intestinal giardiasis. <i>Int J Pancreatol.</i> 1993 Oct;14(2):175-80.		
	16.	CASSIDY, et al. A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. <i>Biochemistry.</i> 1997 Apr 15;36(15):4576-84.		
	17.	CHEN, et al. Identification of two lysosomal membrane glycoproteins. <i>J Cell Biol.</i> 1985 Jul;101(1):85-95.		
	18.	CORRING, et al. Development of digestive enzymes in the piglet from birth to 8 weeks. I. Pancreas and pancreatic enzymes. <i>Nutr Metab.</i> 1978;22(4):231-43.		
	19.	COUET, et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolin-associated proteins. <i>J Biol Chem.</i> 1997 Mar 7;272(10):6252-33.		
	20.	CRAIG, et al. Heat shock proteins: molecular chaperones of protein biogenesis. <i>Microbiol Rev.</i> 1993 Jun;57(2):402-14.		
	21.	CROONENBERGHS, et al. Peripheral markers of serotonergic and noradrenergic function in post-pubertal, caucasian males with autistic disorder. <i>Neuropsychopharmacology.</i> 2000 Mar;22(3):275-83.		
	22.	EDELSON, et al. 3-Cyclohexene-1-glycine, an Isoleucine Antagonist. <i>J. Am. Chem. Soc.</i> 1958; 80(11):2698-2700.		
	23.	ETHRIDGE, et al. Acute pancreatitis results in induction of heat shock proteins 70 and 27 and heat shock factor-1. <i>Pancreas.</i> 2000 Oct;21(3):248-56.		
	24.	FAFOURNOUX, et al. Amino acid regulation of gene expression. <i>Biochem J.</i> 2000 Oct 1;351(Pt 1):1-12.		
	25.	FALLINGBORG, et al. Measurement of gastrointestinal pH and regional transit times in normal children. <i>J Pediatr Gastroenterol Nutr.</i> 1990 Aug;11(2):211-4.		
	26.	FITZSIMMONS, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. <i>N Engl J Med.</i> 1997 May 1;336(18):1283-		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 Applicant's unique citation designation number (optional). *Applicant is to place a checkmark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public when an in file (and by the USPTO in process) no application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is intended to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. There will be no charge upon the individual user. Any comments on the amount of time you require to complete this form will be appreciated for improving this form. Should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Albert Mark Navarro				
Sheet	4	of	7	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^d
	9.		
	27.	GARDNER. Absorption of intact peptides: studies on transport of protein digests and dipeptides across rat small intestine in vitro. Q J Exp Physiol. 1982 Oct;67(4):629-37.	
	28.	GARNER Jr, et al. Porcine Pancreatic Lipase - A Glycoprotein. J Biol Chem. 1972 Jan 25;247(2):561-5.	
	29.	GIGLIO, et al. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr. 1997 Nov;86(11):1162-5.	
	30.	GOFF, et al. Production of abnormal proteins in E. coli stimulates transcription of lon and other heat shock genes. Cell. 1985 Jun;41(2):587-95.	
	31.	GREEN, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414-9.	
	32.	GUPTA, et al. Th1- and Th2-like cytokines in CD34+ and CD8+ T cells in autism. J Neuroimmunol. 1998 May 1;85(1):106-9.	
	33.	HADJIVASSILIOU, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 1996 Feb 10;347(8998):369-71.	
	34.	HORVATH, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999 Nov;135(5):559-63.	
	35.	HUANG, et al. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet. 1997 Oct;6(11):1879-85.	
	36.	HUANG, et al. Mapping of the human APOB gene to chromosome 2p and demonstration of a two-allele restriction fragment length polymorphism. Proc Natl Acad Sci U S A. 1986 Feb;83(3):644-8.	
	37.	JUHL. Fibromyalgia and the serotonin pathway. Altern Med Rev. 1998; 3(5):367-375.	
	38.	KOLLER, et al. Falls and Parkinson's Disease (Abstract). Clin Neuropharmacol. 1989,	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*APPLICANT: Signatures designate: applicant (optional). *APPLICANT is to place a checkmark box if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to be filed by the USPTO to process an application. Confidentiality is preserved by 35 U.S.C. 121 and 37 CFR 1.14. This collection is estimated to take 7 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22311-1460.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Albert Mark Navarro				
Attorney Docket Number	41012-705.201				
Sheet	5	of	7		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7*
		12(2):98-105.	
	39.	LLOYD. Lysosome membrane permeability: implications for drug delivery. Adv Drug Deliv Rev. 2000 Mar 30;41(2):189-200.	
	40.	LUEDTKE, et al. Cathepsin A is expressed in a cell- and region-specific manner in the testis and epididymis and is not regulated by testicular or pituitary factors. J Histochem Cytochem. 2000 Aug;48(8):1131-46.	
	41.	MANNINO, et al. Surveillance for asthma—United States, 1960-1995. MMWR CDC Surveill Summ. 1998 Apr 24;47(1):1-27.	
	42.	MCCORMACK, et al. Localization of the disulfide bond involved in post-translational processing of glycosylasparaginase and disrupted by a mutation in the Finnish-type aspartylglycosaminuria. J Biol Chem. 1995 Feb 17;270(7):3212-5.	
	43.	MELMED, et al. Metabolic markers and gastrointestinal symptoms in children with autism and related disorders. J Pediatr Gastroenterol. 2000; 31:S31-S32.	
	44.	MONONEN, et al. Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycosylasparaginase. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2941-5.	
	45.	NEUER, et al. The role of heat shock proteins in reproduction. Hum Reprod Update. 2000 Mar-Apr;6(2):149-59.	
	46.	Office Action dated 05/24/11 for US Application 12/487,864.	
	47.	PURL, et al. Isolated segmental duodenal ganglioneurosis. Indian Journal of Radiology and Imaging. 2000; 153-154.	
	48.	RIDER, et al. Perspective of biochemical research in the neuronal ceroid-lipofuscinosis. Am J Med Genet. 1992 Feb 15;42(4):519-24.	
	49.	ROTTIER, et al. Lack of PPCA expression only partially coincides with lysosomal storage in galactosialidosis mice: indirect evidence for spatial requirement of the catalytic rather than the protective function of PPCA. Hum Mol Genet. 1998	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant.

*APPLICANT'S single citation disclaimer number (optional) *Applies to in place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.99. The information is required in order to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 121 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1416, Alexandria, VA 22313-1450. DO NOT SEND PREP OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Correspondence by Patent, P.O. Box 1400, Alexandria, VA 22313-1400.

If you need assistance in completing the form, call 1-800-PTO-5176 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Albert Mark Navarro				
Sheet	6	of	7	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Y ²
		Oct;7(11):1787-94.	
	50.	SABRA, et al. Linkage of ileal-lymphoid-nodular hyperplasia (ILNH), food allergy and CNS developmental: evidence for a non-IgE association. <i>Ann Allergy Asth Immunol.</i> 1999; 82:8.	
	51.	SANDLER, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. <i>N Engl J Med.</i> 1999 Dec 9;341(24):1801-6.	
	52.	SCHAFER, et al. Stress kinases and heat shock proteins in the pancreas: possible roles in normal function and disease. <i>J Gastroenterol.</i> 2000;35(1):1-9.	
	53.	SINGH, et al. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. <i>J Neuroimmunol.</i> 1996 May;66(1-2):142-5.	
	54.	STEIN, et al. Nitrogen metabolism in normal and hyperkinetic boys. <i>Am J Clin Nutr.</i> 1984 Apr;39(4):520-4.	
	55.	STEINHERZ, et al. Patterns of amino acid efflux from isolated normal and cystinotic human leucocyte lysosomes. <i>J Biol Chem.</i> 1982 Jun 10;257(11):6041-9.	
	56.	STOLL, et al. Enteral nutrient intake level determines intestinal protein synthesis and accretion rates in neonatal pigs. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2000 Aug;279(2):G288-94.	
	57.	STRADER, et al. Publication Structural basis of β -adrenergic receptor function. <i>FASEB J.</i> 1989 May;3(7):1825-32.	
	58.	THOMAS, et al. Defective protein folding as a basis of human disease. <i>Trends Biochem Sci.</i> 1995 Nov;20(11):456-9.	
	59.	VILANOVA, et al. Preparative isolation of the two forms of pig pancreatic pro-(carboxypeptidase A) and their monomeric carboxypeptidases A. <i>Biochem J.</i> 1985 Aug 1;229(3):603-9.	
	60.	VOLKMAR, et al. Practice parameters for the assessment and treatment of children.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include only if this form with next communication to applicant.

†Applicant's unique chance designation number (optional). ‡Applicant to set price a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.01. This information is required to assist or create a benefit by the public which is to file (and by the USPTO to process) an application.

Confidentiality is governed by 37 U.S.C. 112 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application.

Consent to the USPTO. There will vary depending upon the individual case. Any comments on the accuracy of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-761-9199) and press option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if known		
			Application Number	09/990,909	
			Filing Date	November 16, 2001	
			First Named Inventor	Joan M. Fallon	
			Art Unit	1645	
			Examiner Name	Albert Mark Navarro	
Sheet	7	of	7	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
		adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry. (PART 1) 1999 Dec;38(12 Suppl):32S-54S.		
	61.	VOLKMAR, et al. Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Autism and other Pervasive Developmental Disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. (PART 2) 1999 Dec;38(12):1611-6.		
	62.	WAKEFIELD, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol. 2000 Sep;95(9):2285-95.		
	63.	WAKEFIELD, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351(9103):637-41.		
	64.	WALSH, et al. Heat shock and the role of the HSPs during neural plate induction in early mammalian CNS and brain development. Cell Mol Life Sci. 1997 Feb;53(2):198-211.		
	65.	WEINTRAUB, et al. Morphometric studies of pancreatic acinar granule formation in NCTR-Balb/c mice. J Cell Sci. 1992 May;102 (Pt 1):141-7.		
	66.	WILLIAMS, et al. Eating habits of children with autism. Pediatr Nurs. 2000 May-Jun;26(3):259-64.		
	67.	YOUNGBERG, et al. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci. 1987 May;32(5):472-80.		
	68.	YUAN, et al. Freeze-Thaw Stability of Three Waxy Maize Starch Pastes Measured by Centrifugation and Calorimetry. Cereal Chem. 1998; 75(4):571-573.		
	69.	ZEINER, et al. Mammalian protein RAP46: an interaction partner and modulator of 70 kDa heat shock proteins. EMBO J. 1997 Sep 15;16(18):5483-90.		

Examiner Signature	/Albert M Navarro/	Date Considered	06/27/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is in the (USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 102 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. There will vary according to the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND FEE OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-756-9199) and select option 2.